Drug Phase Transformation and Water Redistribution during Continuous Tablet Manufacturing: A Case Study of Carbamazepine Dihydrate
In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the im...
Saved in:
Published in | Molecular pharmaceutics Vol. 20; no. 7; pp. 3427 - 3437 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Chemical Society
03.07.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the impact of processing conditions and formulation composition on the dehydration behavior of hydrates during continuous manufacturing has not been investigated. Using powder X-ray diffractometry, we monitored the dehydration kinetics of carbamazepine dihydrate in formulations containing dibasic calcium phosphate, anhydrous (DCPA), mannitol, or microcrystalline cellulose. The combined effect of nitrogen flow and vigorous mixing during the continuous mixing stage of tablet manufacture facilitated API dehydration. Dehydration was rapid and most pronounced in the presence of DCPA. The dehydration product, amorphous anhydrous carbamazepine, sorbed a significant fraction of the water released by dehydration. Thus, the dehydration process resulted in a redistribution of water in the powder blend. The unintended formation of an amorphous dehydrated phase, which tends to be much more reactive than its crystalline counterparts, is of concern and warrants further investigation. |
---|---|
AbstractList | In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant fraction of active pharmaceutical ingredients exists as hydrates (wherein water is incorporated stoichiometrically in the crystal lattice), the impact of processing conditions and formulation composition on the dehydration behavior of hydrates during continuous manufacturing has not been investigated. Using powder X-ray diffractometry, we monitored the dehydration kinetics of carbamazepine dihydrate in formulations containing dibasic calcium phosphate, anhydrous (DCPA), mannitol, or microcrystalline cellulose. The combined effect of nitrogen flow and vigorous mixing during the continuous mixing stage of tablet manufacture facilitated API dehydration. Dehydration was rapid and most pronounced in the presence of DCPA. The dehydration product, amorphous anhydrous carbamazepine, sorbed a significant fraction of the water released by dehydration. Thus, the dehydration process resulted in a redistribution of water in the powder blend. The unintended formation of an amorphous dehydrated phase, which tends to be much more reactive than its crystalline counterparts, is of concern and warrants further investigation. |
Author | Arora, Kapildev K. Suryanarayanan, Raj Munjal, Bhushan DeBoyace, Kevin Cao, Fengjuan Krzyzaniak, Joseph F. |
AuthorAffiliation | Drug Product Design Pfizer Worldwide Research and Development Department of Pharmaceutics, College of Pharmacy |
AuthorAffiliation_xml | – name: Department of Pharmaceutics, College of Pharmacy – name: Drug Product Design – name: Pfizer Worldwide Research and Development |
Author_xml | – sequence: 1 givenname: Bhushan orcidid: 0000-0003-2154-9599 surname: Munjal fullname: Munjal, Bhushan organization: Department of Pharmaceutics, College of Pharmacy – sequence: 2 givenname: Kevin surname: DeBoyace fullname: DeBoyace, Kevin organization: Drug Product Design – sequence: 3 givenname: Fengjuan surname: Cao fullname: Cao, Fengjuan organization: Drug Product Design – sequence: 4 givenname: Joseph F. surname: Krzyzaniak fullname: Krzyzaniak, Joseph F. organization: Drug Product Design – sequence: 5 givenname: Kapildev K. orcidid: 0000-0002-7251-7610 surname: Arora fullname: Arora, Kapildev K. email: kapildev.arora@pfizer.com organization: Drug Product Design – sequence: 6 givenname: Raj orcidid: 0000-0002-6322-0575 surname: Suryanarayanan fullname: Suryanarayanan, Raj email: surya001@umn.edu organization: Department of Pharmaceutics, College of Pharmacy |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37232571$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1PG0EMhkcVqHy0f6Eabr0kzMdudrc3FCgggUCQqseVd8ZLBu3OhPk4pEd-OROSIvXWk2359WPZ7xHZs84iISecTTkT_BRUmI5uWC3Bj6AwxalUjLGZ_EQOeVnISS0bsfeR18UBOQrhmTFRlEJ-JgeyElKUFT8kr-c-PdH7JQSkCw829C4zo3GWgtX0N0T09AG1CdGbLr03dPLGPtG5s9HY5FKgC-gGjPQWbOpBxff-D3pG5xvsY0x6TV2fK9_BCH9wZSzSc7Nca5_5X8h-D0PAr7t4TH79vFjMryY3d5fX87ObCUhWxUnNdIdyVoJiqqlZNetF1Tei4rVo6qJgwHvOUZYdV1orzHXXAZONlEXJxUzLY_J9y11595IwxHY0QeEwgMV8RCtqwVh-WcWztNlKlXcheOzblTcj-HXLWbuxoM0WtP9Y0O4syLPfdmtSN6L-mPz78ywot4IN49klb_PV_wF-Ayrnnh8 |
Cites_doi | 10.3390/PHARMACEUTICS13081311 10.1021/acs.oprd.1c00197 10.1002/JPS.21443 10.1002/9781119600800.CH72 10.1016/J.XPHS.2022.08.029 10.1016/J.EJPS.2021.106086 10.1021/JS960117E 10.1248/CPB.44.1065 10.3109/03639048809151997 10.1002/JPS.2600670609 10.3109/10837459809028643 10.1016/j.trac.2021.116181 10.1107/S0567740881007383 10.1016/J.IJPHARM.2021.121065 10.1016/S0731-7085(00)00262-4 10.1016/J.XPHS.2021.01.035 10.1081/PDT-100100540 10.1016/S0169-409X(99)00018-6 10.1016/B978-0-12-813479-5.00003-3 10.1002/JPS.20532 10.1023/A:1015970218980 10.1021/acs.molpharmaceut.1c00217 10.1208/PT040468 10.1021/acs.molpharmaceut.8b00340 10.1002/3527607889.CH8 10.1016/J.POWTEC.2012.04.059 10.1016/j.xphs.2018.07.018 10.1016/J.ADDR.2021.113840 10.1016/J.IJPHARM.2018.12.058 10.1002/CRAT.2170211118 10.1002/JPS.2600640805 10.1038/nrd1550 10.1007/s12247-018-9313-5 10.1016/J.IJPHARM.2018.09.032 10.1016/J.XPHS.2020.12.040 10.1002/(sici)1520-6017(200004)89:4<457::aid-jps3>3.0.co;2-g 10.1002/jps.20191 10.1007/s11095-012-0698-4 |
ContentType | Journal Article |
Copyright | 2023 American Chemical Society |
Copyright_xml | – notice: 2023 American Chemical Society |
DBID | NPM AAYXX CITATION 7X8 |
DOI | 10.1021/acs.molpharmaceut.3c00063 |
DatabaseName | PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1543-8392 |
EndPage | 3437 |
ExternalDocumentID | 10_1021_acs_molpharmaceut_3c00063 37232571 e46649854 |
Genre | Journal Article |
GroupedDBID | --- -~X 123 4.4 53G 55A 5VS 7~N AABXI ABFRP ABMVS ABQRX ABUCX ACGFS ACS ADHLV AEESW AENEX AFEFF AHGAQ ALMA_UNASSIGNED_HOLDINGS AQSVZ CS3 DU5 EBS ED~ F5P GGK GNL H~9 IH9 JG~ P2P RNS ROL UI2 VF5 VG9 W1F ABJNI BAANH CUPRZ NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a307t-80dbe365ac0c98076f27f92718298440a1f11e35b1cddce0a1bba0393345126d3 |
IEDL.DBID | ACS |
ISSN | 1543-8384 |
IngestDate | Fri Aug 16 04:36:07 EDT 2024 Fri Aug 23 01:51:37 EDT 2024 Wed Oct 16 00:38:14 EDT 2024 Thu Jul 06 08:30:33 EDT 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 7 |
Keywords | moisture redistribution dibasic calcium phosphate PCMM continous mixing dehydration continuous manufacturing hydrate carbamazepine drug phase transformation |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a307t-80dbe365ac0c98076f27f92718298440a1f11e35b1cddce0a1bba0393345126d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-2154-9599 0000-0002-7251-7610 0000-0002-6322-0575 |
PMID | 37232571 |
PQID | 2820015471 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2820015471 crossref_primary_10_1021_acs_molpharmaceut_3c00063 pubmed_primary_37232571 acs_journals_10_1021_acs_molpharmaceut_3c00063 |
PublicationCentury | 2000 |
PublicationDate | 2023-07-03 |
PublicationDateYYYYMMDD | 2023-07-03 |
PublicationDate_xml | – month: 07 year: 2023 text: 2023-07-03 day: 03 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular pharmaceutics |
PublicationTitleAlternate | Mol. Pharmaceutics |
PublicationYear | 2023 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
References | ref9/cit9 ref6/cit6 ref3/cit3 ref27/cit27 ref18/cit18 European Medicines Agency (ref8/cit8) 2021 Krogmeier S. (ref4/cit4) 2022 ref11/cit11 ref25/cit25 ref16/cit16 ref29/cit29 European Medicines Agency (ref7/cit7) 2020 ref32/cit32 ref23/cit23 ref39/cit39 ref14/cit14 ref5/cit5 ref31/cit31 ref2/cit2 ref34/cit34 ref37/cit37 ref28/cit28 ref40/cit40 ref20/cit20 ref17/cit17 ref10/cit10 ref26/cit26 ref35/cit35 ref19/cit19 ref21/cit21 ref12/cit12 ref15/cit15 ref42/cit42 ref41/cit41 ref22/cit22 Sheskey P. J. (ref36/cit36) 2020 ref13/cit13 ref33/cit33 ref30/cit30 ref1/cit1 ref24/cit24 ref38/cit38 |
References_xml | – ident: ref5/cit5 doi: 10.3390/PHARMACEUTICS13081311 – volume-title: Committee for Medicinal Products for Human Use (CHMP) year: 2020 ident: ref7/cit7 contributor: fullname: European Medicines Agency – ident: ref11/cit11 doi: 10.1021/acs.oprd.1c00197 – ident: ref35/cit35 doi: 10.1002/JPS.21443 – ident: ref2/cit2 doi: 10.1002/9781119600800.CH72 – ident: ref34/cit34 doi: 10.1016/J.XPHS.2022.08.029 – ident: ref18/cit18 doi: 10.1016/J.EJPS.2021.106086 – ident: ref26/cit26 doi: 10.1021/JS960117E – ident: ref38/cit38 doi: 10.1248/CPB.44.1065 – ident: ref13/cit13 doi: 10.3109/03639048809151997 – ident: ref42/cit42 doi: 10.1002/JPS.2600670609 – ident: ref21/cit21 doi: 10.3109/10837459809028643 – ident: ref24/cit24 doi: 10.1016/j.trac.2021.116181 – ident: ref29/cit29 doi: 10.1107/S0567740881007383 – ident: ref10/cit10 doi: 10.1016/J.IJPHARM.2021.121065 – ident: ref37/cit37 doi: 10.1016/S0731-7085(00)00262-4 – ident: ref6/cit6 – ident: ref9/cit9 doi: 10.1016/J.XPHS.2021.01.035 – ident: ref23/cit23 doi: 10.1081/PDT-100100540 – ident: ref41/cit41 doi: 10.1016/S0169-409X(99)00018-6 – start-page: 383 volume-title: How to Design and Implement Powder-To-tablet Continuous Manufacturing Systems year: 2022 ident: ref4/cit4 doi: 10.1016/B978-0-12-813479-5.00003-3 contributor: fullname: Krogmeier S. – ident: ref25/cit25 doi: 10.1002/JPS.20532 – ident: ref22/cit22 doi: 10.1023/A:1015970218980 – volume-title: Handbook of Pharmaceutical Excipients year: 2020 ident: ref36/cit36 contributor: fullname: Sheskey P. J. – ident: ref17/cit17 doi: 10.1021/acs.molpharmaceut.1c00217 – ident: ref20/cit20 doi: 10.1208/PT040468 – ident: ref31/cit31 doi: 10.1021/acs.molpharmaceut.8b00340 – volume-title: Committee for Medicinal Products for Human Use year: 2021 ident: ref8/cit8 contributor: fullname: European Medicines Agency – ident: ref14/cit14 doi: 10.1002/3527607889.CH8 – ident: ref27/cit27 doi: 10.1016/J.POWTEC.2012.04.059 – ident: ref39/cit39 doi: 10.1016/j.xphs.2018.07.018 – ident: ref1/cit1 doi: 10.1016/J.ADDR.2021.113840 – ident: ref15/cit15 doi: 10.1016/J.IJPHARM.2018.12.058 – ident: ref30/cit30 doi: 10.1002/CRAT.2170211118 – ident: ref12/cit12 doi: 10.1002/JPS.2600640805 – ident: ref40/cit40 doi: 10.1038/nrd1550 – ident: ref3/cit3 doi: 10.1007/s12247-018-9313-5 – ident: ref28/cit28 doi: 10.1016/J.IJPHARM.2018.09.032 – ident: ref32/cit32 doi: 10.1016/J.XPHS.2020.12.040 – ident: ref33/cit33 doi: 10.1002/(sici)1520-6017(200004)89:4<457::aid-jps3>3.0.co;2-g – ident: ref16/cit16 doi: 10.1002/jps.20191 – ident: ref19/cit19 doi: 10.1007/s11095-012-0698-4 |
SSID | ssj0024523 |
Score | 2.435155 |
Snippet | In recent years, continuous tablet manufacturing technology has been used to obtain regulatory approval of several new drug products. While a significant... |
SourceID | proquest crossref pubmed acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 3427 |
Title | Drug Phase Transformation and Water Redistribution during Continuous Tablet Manufacturing: A Case Study of Carbamazepine Dihydrate |
URI | http://dx.doi.org/10.1021/acs.molpharmaceut.3c00063 https://www.ncbi.nlm.nih.gov/pubmed/37232571 https://search.proquest.com/docview/2820015471 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3LTtwwFLVaKlXd8OiLoYCMVLEi0_iR2OluNIBQJSrUBpVdZDt2iyoSNEkWw7Jf3msnw0CrirKMk1iJc-1zYvuci9B7DRAHw5yLeOpkxK11kcxSGXmzqkQ4J02Y0D_9nJ6c808XycVSx_3nCj4lH5Rpxle1F54OU7xjZgKyPkXPqIgzn69hMv26NNhLQk43oAYskkzy52jvwao8NJnmPjT9g28G3DleQ_lCvdNvN_k57lo9Njd_mzk-5pXW0erAQ_GkD5wN9MRWL9H-WX_t_ADnS11Wc4D38dnS4nr-Cv06nHXffVljcX6H-tYVVlWJvwGBneEvXvJ7m1AL94JI7O2wLquu7hqce9lWi09V1Xl9RTj_EU_w1FfrNzjOce3gaKbVlbqx10CI8eHlj3np7S1eo_Pjo3x6Eg3ZHCIF40gLUFhqy9JEmdhkMhapo8JlFLCRZpLzWBFHiGWJJqYsjYVjrZVXDjMOpCQt2Ru0UtWV3URY0MRRy4UupeVWxVLBuOMyolLAWq7dCEEwNsXQG5siLLRTUvjCe-1eDO0-QnTx5Yvr3uXjf27aW8RIAX3SL7SoykLzFfAbG7ipICP0tg-e22qZAA6bCLL12Gd8h174VPdhqzDbRivtrLM7QIhavRs6wG-eiAuM |
link.rule.ids | 315,783,787,2774,27090,27938,27939,57072,57122 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BkYAL78fydCXUU7PEsRM73FZbqgW6VQWpqNRDZCc2VKhJtUkO2yO_nLGT7lIkxOMYJxk5o7Hniz3fZ4BXGlMcTnM24ImVATfGBjJNZODEqmJhrSz8gv58P5kd8vdH8dFQVem4MNiJBi01fhN_rS5AX7u209rxT4eV3jErfIK9CtdiEQp3esFk-mmtsxf7o90QIbBAMsmvw-YfTbkMVTSXM9RvYKdPP7u34XjVcV918m3ctXpcnP-i6fh_X3YHbg2olEz6MLoLV0x1D7YO-meX2yRbs7SabbJFDtaC18v78H1n0X1xbY0h2U9AuK6IqkryGeHsgnx0BODV8Vqkp0cSJ451UnV115DMkbhaMldV59gW_v4bMiFTZ9aVOy5JbfFqodWpOjdnCI_JzsnXZenELh7A4e7bbDoLhrMdAoWzSouJsdSGJbEqwiKVoUhsJGwaYaaMUsl5qKil1LBY06IsC4PXWivHI2YcIUpSsoewUdWVeQxERLGNDBe6lIYbFUqFs5BNqUow83JtR-Dcng9js8n9tntEc9d4ye_54PcRRBcBkJ_1mh9_89LmRajkOELdtouqDLovx59aj1QFHcGjPoZWZplARBsL-uRf-_gSbsyy-V6-927_w1O4GSH08kXE7BlstIvOPEeo1OoXfkz8AJgzE_U |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSBWXUt5LC7gS6qnZrh0ncbitdlmVR6sVbEVvlp3YUFVNVpvksD32lzPjpLsUCfE4xkksZzTj74vtb4aQNwYgDqY5F4jYyUBY6wKZxjLAZFVR4pzM_IL-8Ul8dCo-nEVn3YIbamFgEBX0VPlNfIzqee66DAPsENsvS9Sgdqu9_TDzIHuX3IsSxrGCwXD0ZZ1rL_Ll3YAlhIEMpdgke3_sClEqq26j1G-op4egyQOiVoP3J08u-k1t-tnVL3kd___rtslWx07psHWnh-SOLR6R_Wn77PKAztZqreqA7tPpOvH18jG5Hi-ab9hWWTr7iRCXBdVFTr8CrV3QzygEXpXZoq1MkmKSrPOiKZuKzlDMVdNjXTSouvD339IhHWG3eOxxSUsHVwujL_WVnQNNpuPz78sck148IaeTd7PRUdDVeAg0zC41AGRubBhHOhtkqRwkseOJSzkgJk-lEAPNHGM2jAzL8jyzcG2MRj1xKICqxHn4lGwUZWGfE5rwyHErEpNLK6weSA2zkUuZjgGBhXE9gqZXXYxWym-_c6aw8ZbdVWf3HuE3TqDmbe6Pv3lp78ZdFEQqbr_owoL5FPzcesaasB551vrRqtswAWYLLvziX8f4mmxOxxP16f3Jxx1ynwMD82eJw12yUS8a-xIYU21e-bD4ATAuFm8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Drug+Phase+Transformation+and+Water+Redistribution+during+Continuous+Tablet+Manufacturing%3A+A+Case+Study+of+Carbamazepine+Dihydrate&rft.jtitle=Molecular+pharmaceutics&rft.au=Munjal%2C+Bhushan&rft.au=DeBoyace%2C+Kevin&rft.au=Cao%2C+Fengjuan&rft.au=Krzyzaniak%2C+Joseph+F.&rft.date=2023-07-03&rft.pub=American+Chemical+Society&rft.issn=1543-8384&rft.eissn=1543-8392&rft.volume=20&rft.issue=7&rft.spage=3427&rft.epage=3437&rft_id=info:doi/10.1021%2Facs.molpharmaceut.3c00063&rft.externalDocID=e46649854 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1543-8384&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1543-8384&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1543-8384&client=summon |